UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
Securities registered pursuant to Section 12(b) of the Act: | ||
Title of each class | Trading Symbols | Name of exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | |
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e)On June 5, 2024, Globus Medical, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders approved the amendment to the 2021 Equity Incentive Plan (the “2021 Equity Incentive Plan Amendment”). The 2021 Equity Incentive Plan Amendment had been previously recommended for approval by the Company’s Compensation Committee of the Board of Directors and previously approved by the Company’s Board of Directors, in each case, subject to stockholder approval. The 2021 Equity Incentive Plan Amendment became effective as of the date of such stockholder approval – June 5, 2024.
The material features of the 2021 Equity Incentive Plan, as amended, are described in the section entitled Proposal 2; Approval of Amendment to the 2021 Equity Incentive Plan appearing on pages 21-22 of the Company’s definitive Proxy Statement on Schedule 14A filed on April 26, 2024 in connection with the 2024 Annual Meeting, which description is incorporated herein by reference. A copy of the 2021 Equity Incentive Plan as Amended is filed as Exhibit 10.1 hereto and incorporated herein by reference.
Item 5.07. Submission of Matters to a Vote of Security Holders.
The Annual Meeting was held on June 5, 2024. At the Annual Meeting, the stockholders voted on the following four proposals and cast their votes as described below.
Proposal 1
The individuals listed below were each elected at the Annual Meeting to serve a three-year term on the Company’s Board of Directors.
|
|
|
|
Nominee | For | Withhold | Broker Non-Vote |
David D. Davidar | 263,717,947 | 59,470,766 | 6,372,297 |
James R. Tobin | 256,480,132 | 66,708,581 | 6,372,297 |
Stephen T. Zarrilli | 319,986,786 | 3,201,927 | 6,372,297 |
Daniel J. Wolterman | 322,452,687 | 736,026 | 6,372,297 |
Proposal 2
Approval of the Amendment to the 2021 Equity Incentive Plan:
|
|
|
|
For | Against | Abstain | Broker Non-Vote |
244,115,224 | 78,950,353 | 123,136 | 6,372,297 |
Proposal 3
Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. This proposal was approved.
|
|
|
|
For | Against | Abstain | Broker Non-Vote |
329,276,382 | 252,325 | 32,303 | 0 |
Proposal 4
A non-binding advisory vote to approve the compensation of the Company’s named executive officers, as described in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission. This proposal was approved.
|
|
|
|
For | Against | Abstain | Broker Non-Vote |
315,355,286 | 7,709,004 | 124,423 | 6,372,297 |
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
|
Exhibit Number | Description |
10.1 | |
104 | Cover Page Interactive Data file (formatted in Inline XBRL) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| GLOBUS MEDICAL, INC. |
|
| (Registrant) |
|
|
|
Dated: | June 6, 2024 | /s/ KELLY G. HULLER |
|
|
|
|
| Kelly G. Huller |
|
| Senior Vice President, General Counsel and Corporate Secretary |